Wintech Nano
688757
CHANGFU CO.,LTD
871396
DIER CHEMICAL
831304
4
CHENGUANG MEDICAL
430300
5
TLC
873576
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -5.32%110.84M | -0.62%28.24M | -2.51%28.55M | -4.33%28.09M | -13.46%25.96M | -15.68%117.06M | -12.66%28.42M | -13.17%29.28M | -21.13%29.36M | -15.11%30M |
Operating revenue | -5.32%110.84M | -0.62%28.24M | -2.51%28.55M | -4.33%28.09M | -13.46%25.96M | -15.68%117.06M | -12.66%28.42M | -13.17%29.28M | -21.13%29.36M | -15.11%30M |
Cost of revenue | -14.09%60.84M | -11.61%15M | -15.55%15.42M | -12.78%15.24M | -16.18%15.18M | -16.13%70.82M | -13.26%16.97M | -10.52%18.26M | -19.79%17.48M | -20.14%18.11M |
Gross profit | 8.12%50M | 15.68%13.24M | 19.11%13.13M | 8.09%12.85M | -9.32%10.79M | -14.98%46.24M | -11.75%11.44M | -17.25%11.02M | -23.02%11.89M | -6.11%11.89M |
Operating expense | -19.85%40.28M | -21.86%9.69M | -24.56%9.79M | -19.67%10.46M | -12.78%10.33M | 1.04%50.25M | 3.30%12.4M | 0.00%12.98M | 1.31%13.02M | -0.39%11.85M |
Selling and administrative expenses | -28.15%22.36M | -23.32%5.42M | -26.42%5.75M | -33.00%5.69M | -28.98%5.49M | -7.42%31.11M | -9.57%7.07M | -13.16%7.82M | -3.67%8.5M | -2.97%7.73M |
-Selling and marketing expense | -35.42%6.23M | -32.91%1.42M | -41.16%1.38M | -35.50%1.66M | -32.24%1.77M | -1.41%9.65M | -14.27%2.12M | -6.67%2.34M | 6.35%2.58M | 9.56%2.61M |
-General and administrative expense | -24.88%16.12M | -19.21%4M | -20.14%4.38M | -31.91%4.03M | -27.32%3.72M | -9.89%21.46M | -7.40%4.95M | -15.66%5.48M | -7.48%5.92M | -8.33%5.12M |
Research and development costs | -20.16%3.78M | -16.49%1.01M | -36.51%800K | -10.97%1.06M | -15.31%913K | 7.61%4.74M | 5.48%1.21M | 7.88%1.26M | 7.92%1.19M | 9.44%1.08M |
Depreciation amortization depletion | -1.81%14.14M | -20.95%3.26M | -16.96%3.24M | 11.16%3.71M | 29.36%3.93M | 22.83%14.4M | 35.57%4.12M | 38.90%3.9M | 13.79%3.34M | 3.33%3.04M |
-Depreciation and amortization | -1.81%14.14M | -20.95%3.26M | -16.96%3.24M | 11.16%3.71M | 29.36%3.93M | 22.83%14.4M | 35.57%4.12M | 38.90%3.9M | 13.79%3.34M | 3.33%3.04M |
Operating profit | 342.32%9.72M | 470.25%3.55M | 269.83%3.33M | 310.12%2.39M | 880.43%451K | -186.09%-4.01M | -199.58%-958K | -685.67%-1.96M | -143.91%-1.14M | -94.06%46K |
Net non-operating interest income expense | 21.92%-812K | 85.67%-48K | 46.00%-162K | 4.00%-264K | -160.00%-338K | -185.71%-1.04M | -303.61%-335K | -265.85%-300K | -164.42%-275K | -36.84%-130K |
Non-operating interest income | -42.86%88K | -33.33%20K | -67.31%17K | -53.85%24K | 35.00%27K | 275.61%154K | 57.89%30K | 271.43%52K | 1,633.33%52K | 300.00%20K |
Non-operating interest expense | -24.62%900K | -81.37%68K | -49.15%179K | -11.93%288K | 143.33%365K | 194.81%1.19M | 257.84%365K | 266.67%352K | 205.61%327K | 50.00%150K |
Other net income (expense) | 97.97%-894K | 99.62%-162K | 98.37%-7K | -20.94%-410K | -25.00%-315K | -3,445.10%-43.99M | -12,282.42%-42.97M | -150.12%-430K | -221.51%-339K | -148.00%-252K |
Gain on sale of security | 116.46%130K | ---- | ---- | ---- | ---- | -29.51%-790K | ---- | ---- | ---- | ---- |
Special income (charges) | 98.62%-596K | 99.79%-91K | -737.50%-67K | 24.18%-116K | -19.70%-322K | -2,308.25%-43.11M | -426,650.00%-42.68M | -100.59%-8K | -191.62%-153K | -160.86%-269K |
-Less:Impairment of capital assets | --0 | ---- | ---- | ---- | ---- | --42M | ---- | ---- | ---- | ---- |
-Less:Other special charges | -46.06%596K | -86.52%91K | 737.50%67K | -24.18%116K | 19.70%322K | -2.90%1.11M | 221.43%675K | -97.39%8K | -66.95%153K | 70.25%269K |
Other non- operating income (expenses) | -360.22%-428K | -140.36%-201K | 114.22%60K | -58.06%-294K | -58.82%7K | -244.44%-93K | 82.42%498K | 14.75%-422K | -266.07%-186K | -79.52%17K |
Income before tax | 116.34%8.01M | 107.54%3.34M | 217.50%3.16M | 197.89%1.71M | 39.88%-202K | -974.27%-49.04M | -8,419.55%-44.26M | -342.30%-2.69M | -163.36%-1.75M | -127.91%-336K |
Income tax | 143.96%160K | 107.22%41K | -28.07%41K | -52.44%39K | -40.00%39K | -305.65%-364K | -1,821.21%-568K | 3.64%57K | 228.00%82K | 1.56%65K |
Net income | 116.13%7.85M | 107.54%3.3M | 213.57%3.12M | 191.38%1.67M | 39.90%-241K | -996.06%-48.67M | -8,855.91%-43.69M | -360.32%-2.75M | -166.93%-1.83M | -135.18%-401K |
Net income continuous Operations | 116.13%7.85M | 107.54%3.3M | 213.57%3.12M | 191.38%1.67M | 39.90%-241K | -996.06%-48.67M | -8,855.91%-43.69M | -360.32%-2.75M | -166.93%-1.83M | -135.18%-401K |
Minority interest income | ||||||||||
Net income attributable to the parent company | 116.13%7.85M | 107.54%3.3M | 213.57%3.12M | 191.38%1.67M | 39.90%-241K | -996.06%-48.67M | -8,855.91%-43.69M | -360.32%-2.75M | -166.93%-1.83M | -135.18%-401K |
Preferred stock dividends | -21.46%12.31M | -16.11%3.29M | -3.24%3.79M | 0.33%3.92M | -99.87%5K | 1.01%15.67M | 1.61%3.92M | 1.74%3.92M | 3.55%3.91M | -2.63%3.93M |
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 93.07%-4.46M | 100.02%10K | 89.99%-667K | 60.83%-2.25M | 94.32%-246K | -538.06%-64.35M | -1,318.62%-47.61M | -138.63%-6.67M | -452.65%-5.74M | -49.53%-4.33M |
Basic earnings per share | ||||||||||
Diluted earnings per share | ||||||||||
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |